Emerging technologies that reduce the economic and environmental costs of anaesthesia have had limited assessment. We hypothesised that automated control of end-tidal gases, a new feature in anaesthesia machines, will consistently reduce volatile agent consumption cost and greenhouse gas emissions. As part of the planned replacement of anaesthesia machines in a tertiary hospital, we performed a prospective before and after study comparing the cost and greenhouse gas emissions of isoflurane, sevoflurane and desflurane when using manual versus automated control of end-tidal gases. We analysed 3675 general anaesthesia cases with inhalational agents: 1865 using manual control and 1810 using automated control. Volatile agent cost was $18.87/hour using manual control and $13.82/hour using automated control: mean decrease $5.05/hour (95% confidence interval: $0.88-9.22/hour, P=0.0243). The 100-year global warming potential decreased from 23.2 kg/hour of carbon dioxide equivalents to 13.0 kg/hour: mean decrease 10.2 kg/hour (95% confidence interval: 2.7-17.7 kg/hour, P=0.0179). Automated control reduced costs by 27%. Greenhouse gas emissions decreased by 44%, a greater than expected decrease facilitated by a proportional reduction in desflurane use. Automated control of end-tidal gases increases participation in low-flow anaesthesia with economic and environmental benefits.
Low-flow anaesthesia is synonymous with reduced economic and environmental costs. The goal of consistent low-flow practise in clinical practice, however, remains elusive because of its complexities 1 . There is a need for technology to simplify the management of fresh gas flow and volatile agents 2 , and recent advances include the availability of automated control of endtidal gases (Et control) for oxygen (O 2 ), nitrous oxide (N 2 O) and volatile anaesthetic agents. Anaesthesia machines with these capabilities control both the gas mixture and fresh gas flow to deliver selected endtidal concentrations.
Theoretical advantages include preventing under delivery of volatile anaesthetic agents and O 2 . This reduces the need for anaesthetists to continually monitor and change the fraction of inspired gases and fresh gas flow during a case. Ultimately this allows for more time to attend to other aspects of patient care and may lead to increased compliance and participation in low-flow anaesthesia. Anaesthesia machines with automated control of end-tidal gases are commercially available in Australia, New Zealand, United Kingdom and most of Europe and Asia.
Low-flow anaesthesia using model-based predictive displays with automated feedback or manual control systems have been well described [3] [4] [5] [6] and these concepts have been evaluated previously for their pharmacoeconomic benefits 7, 8 , but never in a clinical setting. This growing body of evidence aims to modify the way volatile agents are delivered to manage the disproportionate increases in inhalational agent costs compared to patient workload 9 and their impact on climate change 10 . Therefore, our hypothesis was, compared to the conventional practice of using manual control in the delivery of volatile agents, the automated control of end-tidal anaesthetic gases in a clinical setting would produce a significant difference in volatile agent consumption cost and the rate of greenhouse gas emissions.
METHODS
This study was conducted at the Northern Hospital, a university teaching hospital in Melbourne, Australia. Following approval from the Northern Hospital's Human Research Ethics Committee (approval number LR22/11), we performed a prospective before and after study evaluating automated and manual control of end-tidal gases after planned replacement of anaesthesia machines. Northern Hospital has six operating theatres catering to all specialties except cardiac and neurosurgery. it averages over 10,000 surgical patients per year, of which approximately three-quarters undergo general anaesthesia with an inhalational agent. All patients undergoing elective and emergency surgery were considered participants, with anaesthesia technique, demographics, surgical specialty, American Society of Anesthesiologists physical status classification and surgical time recorded electronically. inclusion criteria included all patients requiring general anaesthesia with a volatile agent. Exclusion criteria were total intravenous anaesthesia, electroconvulsive therapy, sedation and regional anaesthesia without a volatile agent general anaesthetic. We used cases instead of patients to present our results in order to take into account the probability of a patient having more than one episode of general anaesthesia with an inhalational agent during the study.
The primary outcome measure was volatile agent cost per hour of inhalational general anaesthesia. Costs were calculated by the product of the number of volatile agent bottles and their acquisitions costs as recorded by pharmacy each week. All volatile agent bottles were tracked electronically. We used one bottle at a time to refill all vaporisers in the operating theatres to their maximum before the start of each week. if a bottle was not completely used, it was not recorded as used by the pharmacy, which created a margin of error of minus one bottle at the end of each study phase. There were three study phases and we did consider these to be significant. inhalational general anaesthesia hours were derived from the surgical start and surgical end times. Their weekly totals were tabulated by health information services. All costs were measured in Australian dollars. Secondary outcome measures were greenhouse gas emissions measured through the 100-year global warming potential (GWP 100 ) index, carbon dioxide (CO 2 ) absorbent (Medisorb) and fresh gas (O 2 , air and N 2 O) costs. Table 1 shows the GWP 100 of associated greenhouse gas emissions expressed as carbon dioxide equivalents per kilogram from each bottle of volatile agent factoring in the hepatic metabolism of sevoflurane as 3%, isoflurane 0.2% and desflurane 0.02% 11 . Weekly CO 2 absorbent and fresh gas costs were calculated by our supply department.
in 2010, all six operating theatres were using the same brand of anaesthesia machine (Anaesthesia Delivery Unit Carestation, Datex-Ohmeda, Helsinki, Finland) with manual control of fresh gas flow and end-tidal concentrations of O 2 , N 2 O and volatile anaesthetic agents ( Figure 1 ). in May 2011, these were replaced by machines (Aisys Carestation, GE Healthcare, Little Chalfont, United Kingdom) fitted with software allowing for automated control of endtidal gases ( Figure 2 ). Technical specifications are described in further detail in Table 2 .
We started with a 12-week manual phase (January to April 2011) during which all outcomes were measured using the Anaesthesia Delivery Unit Carestation with manual control. This was followed by a preparation and education phase of two months 
TabLe 2 Technical specifications
Et control is an optional function that allows the clinician to set a target end-tidal oxygen (O 2 ) and an end-tidal anaesthetic agent (AA) concentration. it uses a special multiplexing fresh gas module inserted in a standard compact airway module to sample end-tidal gases. Then, via a proprietary algorithm, it first adjusts the fraction of inspired O 2 or AA to achieve set targets. if the response is not fast enough, it then proceeds to change the fresh gas flow (0.5-6 l/minute). The end-tidal AA overshoot that occurs is less than 20% of the target value or an absolute value of 0.4% (whichever is greater). The time required to stabilise within 5% of the target value or an absolute value of 0.2% (whichever is greater) is less than 200 seconds.
The fresh gas module also samples fresh gas every three minutes. if the concentrations in fresh gas do not match the dialled AA or O 2 concentrations, Et control is automatically exited. This also occurs if there are leaks in the patient sampling system or circuit, and if set targets are unable to be achieved.
The default minimum flow rate for sevoflurane is 2 l/minute compared to desflurane and isoflurane which starts at 0.5 l/minute. The anaesthetist, however, can manually change the minimum flow rates to 0.5-6 l/minute at anytime during a case.
(April to May 2011) to introduce the Aisys Carestation with Et control to all medical, nursing and technical anaesthesia staff. A 12-week Et control phase (July to October 2011) was then implemented for comparison. During the Et control phase, we asked anaesthetists to complete voluntary case report forms on whether Et control was used and reasons for not using Et control.
Statistical analyses
A computerised statistical package (Small Stata 12.0 for Mac [StrataCorp, Texas, USA]) was used for data analysis and descriptive statistics. Patient baseline characteristics and categorical variables were compared by the χ 2 test and continuous variables were tested for normality and compared by a twosample Wilcoxon rank-sum (Mann-Whitney) test. We reported mean differences, 95% confidence intervals and considered P values of <0.05 as statistically significant. While non-randomised, we used the relevant sections of the Consolidated Standards of Reporting Trials guidelines to report this study 12 .
RESULTS
There were no statistically significant differences in our case load mix between the manual and Et control phases for age, gender, American Society of Anesthesiologists physical status, surgical specialities and paediatric general anaesthesia cases ( Table 3) . Hospital acquisition cost per bottle of volatile agents remained the same during the study: 250 ml isoflurane=$80, 250 ml sevoflurane=$147 and 240 ml desflurane=$235. We evaluated 5358 surgical patients, of whom 3675 received general anaesthesia with a volatile agent. Of these patients, 1865 were in the manual phase and 1810 in the Et control phase (Figure 3 ). The weekly general anaesthesia hours over each 12-week period were 178 hours (standard deviation [SD] 24) for the manual phase and 160 hours (SD 11) for the Et control phase. From the 1810 surgical cases in the Et control phase (Figure 4) , 1169 (65%) had voluntary case report forms returned. Of these, anaesthetists chose to use automated control of end-tidal gases in 1036 cases and not to use automated control of end-tidal gases in 133 cases. Volatile agent cost per hour (Table 4 and Figure 5 ) decreased from $18.87 (SD $6.15) in the manual phase to $13.82 (SD $3.27) in the Et control phase, a reduction of $5.05 (95% confidence interval [Ci]: $0.88 to $9.22, P=0.0243) or 27%.
The rate of greenhouse gas emissions (Table 4 and Figure 5 ) was 23.2 kg/hour (SD 10.8) in the manual phase and 13.0 kg/hour (SD: 6.2) in the Et control phase, a reduction of 10.2 kg/hour (95% Ci: 2.7-17.7 kg/hour, P=0.0179) or 44%. During the manual phase, desflurane accounted for 17.6% of total bottles used, sevoflurane 82.0% and isoflurane 0.4%. During the Et control phase the percentage of desflurane use decreased to 11.8%, while sevoflurane's consumption increased to 87.6% and the use of isoflurane remained unchanged. To calculate the approximate cost and greenhouse gas emission savings the reduction in desflurane use contributed, we retrospectively looked at a 12-week phase one year prior (July to September 2010). During this retrospective phase, weekly general anaesthesia hours were 153 hours (SD 20) and volatile agent cost per hour was $17.33 (SD $3.77), $1.54 (95% Ci: -$2.78-5.86) less than the manual phase and 
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During planned replacement of hospital anaesthesia machines, we performed a before and after study evaluating the financial and environmental costs of changing from manual to automated control of end-tidal anaesthetic gases. For this pharmacoeconomic study, we evaluated over 3500 episodes of general anaesthesia cases. Consistent with our hypotheses, we found that volatile agent cost per hour decreased by over 25% following the introduction of Et control. We also found that the rate of greenhouse Et control $/kg gas emissions decreased by more than 40%. This represents a cost saving of approximately $40,000 and 80 tonnes of CO 2 equivalents every year at our hospital. The primary benefit of Et control is increased use of low-flow anaesthesia by anaesthetists, which is ultimately how financial and environmental savings are generated 15, 16 . One of the problems for maintaining a strict low-flow policy is that adherence to the policy by anaesthetists is inconsistent and decreases over time 17 . This problem with adherence is because manual low-flow anaesthesia increases the workload and vigilance required to titrate end-tidal concentrations. Manual low-flow anaesthesia is also associated with greater concerns about over or under-dosing volatile agents due to greater differences between the volatile agent composition within the breathing system and the composition being delivered 18 . Constant advocacy, education and feedback to anaesthetists is required to maintain adherence to a low-flow policy 19, 20 . An important advantage of having automated control is ease of use, facilitating low-flow anaesthesia and therefore possibly enhancing adherence to a low-flow policy over time. We found a consistent reduction in volatile use throughout the 12 weeks of the Et control phase of our study. in addition to low-flow anaesthesia, an opportunity exists to further decrease greenhouse gas emissions through the choice of volatile agents. Desflurane is more environmentally harmful than either sevoflurane or isoflurane 11, 14 . Per bottle, desflurane is approximately 20 times more pollutant than sevoflurane and five times more than isoflurane (Table 1) . When taking into account the agents' minimum alveolar concentration and molecular weight, these ratios increase to 50 and 25, respectively, for a given fresh gas flow rate. This explains why an unexpected shift from desflurane to sevoflurane use resulted in a larger than expected reduction in calculated greenhouse gas emissions. The most likely explanation for this shift is that once automated control has commenced for one volatile agent (most commonly sevoflurane), it becomes problematic to switch over to desflurane because a safety feature is triggered when multiple agents are detected, exiting automatic control mode.
Automated control of end-tidal gases has been associated with a 65% decrease of inhalational agent usage when compared to manually controlled anaesthesia 7 . One reason our results differ is because we purposely designed this study based on an 'everyday' teaching hospital scenario, with a heterogenous but representative mix of consultants, registrars and surgical patients to see what the net effect would be. This meant that the use of Et control was not compulsory, and from our voluntary case report forms we estimated a 60% compliance (Figure 4) . The anaesthetists who did not return a case report form were unlikely to have used Et control. Reasons reported for not using Et control included overlooking its availability, quick surgical cases, leaks in the breathing system often due to an inadequately placed airway device and paediatric patients six years of age or younger. For paediatric patients, concerns still remain in our, and other, departments about circle system resistance and dead space, and the safety profile of low-flow anaesthesia for children 21 . Furthermore, gas leaks associated with uncuffed endotracheal tubes would trigger a safety check, exiting the automated control mode and defaulting to high fresh gas flows of 6 l/minute. However, given that paediatric hours in each phase accounted for approximately 2.5% of total surgical hours, it is unlikely that the avoidance of Et control during these cases would have had an important influence on our results.
Reasons for not using minimum flows of 0.5 l/minute included concerns among some anaesthetists about the regulatory guidelines in Australia that recommend flow rates not less than 2 l/minute when using sevoflurane because of its potential renal toxic by-product Compound A 22, 23 . A recent editorial by Feldman, however, questions these limitations 2 , with countries such as New Zealand, the United Kingdom, Japan and most of Europe having no recommendations on minimum fresh gas flow rates 24 .
Surprisingly, the cost of CO 2 absorbents (Medisorb) did not rise. The most likely reason is because different canister designs were used in each period: 600g in the manual phase and 800g in the Et control phase. CO 2 absorbents in larger canisters have consistently been shown to have higher absorptive capacities 25, 26 . This is because an absorbent is at its most efficient when a patient's tidal volume is equal to the void space (the air between the granules) within the canister 27 .
Our study had several limitations. First, it is a single institution study, which may limit generalisation to other hospitals, particularly specialist paediatric centres. Although, our teaching hospital has a varied workload with similarities to other institutions. Second, we did not control the choice of volatile agent, meaning that savings were generated not only from increased participation in low-flow anaesthesia but also from the choice of volatile agents used. Further savings could have been generated with increased use of isoflurane. Third, there is an increased risk of bias and the Hawthorne effect in our results because we did not randomise patients to manual or automated control. increased use of low-flow anaesthesia in a metropolitan teaching hospital was associated with decreases of over 25% in volatile agent costs without any significant change in CO 2 absorbent, air, O 2 and N 2 O costs. The higher than expected environmental savings were due to reduced desflurane use from both lower fresh gas flows and sevoflurane substitution. We conclude that anaesthesia machines with the option of automated control of end-tidal gases can significantly decrease volatile agent consumption with financial and environmental benefits by increasing participation in low-flow anaesthesia.
